Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,168,524 papers from all fields of science
Search
Sign In
Create Free Account
SF-733
Known as:
SF 733
, SF733
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Ribostamycin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1975
1975
Bioconversion of ribostamycin (SF-733). III. Formation, structure and synthesis of 3-N-carboxymethyl ribostamycin.
Michio Kojima
,
Shigeharu Inouye
,
T. Niida
Journal of antibiotics (Tokyo. )
1975
Corpus ID: 29716374
A new inactivated product of ribostamycin (SF-733), 3-N-carboxymethyl ribostamycin, was obtained from the broth of Streptomyces…
Expand
Highly Cited
1970
Highly Cited
1970
Studies on antibiotic SF-733. A new antibiotic. II. Chemical structure of antibiotic SF-733.
E. Akita
,
T. Tsuruoka
,
N. Ezaki
,
T. Niida
Journal of antibiotics (Tokyo. )
1970
Corpus ID: 35543823
A new antibiotic SF-7331) gave neamine2) and methyl D-riboside on acid methanolysis and a furanoside nature of the ribose moiety…
Expand
1970
1970
Studies on antibiotic SF-733, a new antibiotic. I. Taxonomy, isolation and characterization.
T. Shomura
,
N. Ezaki
,
T. Tsuruoka
,
T. Niwa
,
E. Akita
Journal of antibiotics (Tokyo. )
1970
Corpus ID: 2102102
A new antibiotic SF-733 inhibiting both Gram-negative and Gram-positive bacteria was isolated from Streptomyces ribosidificus nov…
Expand
1970
1970
Synthesis of an aminocyclitol antibiotic, SF-733 (ribostamycin).
E. Akita
,
T. Ito
,
T. Tsuruoka
,
T. Niida
Antimicrobial Agents and Chemotherapy
1970
Corpus ID: 29078505
1968
1968
A method for producing a novel antibiotic SF-733
T. Shomura
,
N. Ezaki
,
T. Niida
,
T. Tsuruoka
,
T. Niwa
,
E. Akita
1968
Corpus ID: 80326286
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE